Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:41:12.904Z.
Calculation as of: 2026-10-06T22:41:12.904Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 719625f658538d7511a1815ebd8f3969041d2dee7d9c9a78aa46ea1e1d2f6eab
PEG RATIO
N/A
CapsoVision, Inc.
Market Cap
$324.76M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| CapsoVision, Inc. (CV) | $324.76M | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.71M | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | N/A |
| Agenus Inc. (AGEN)vs › | $311.90M | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
